Novo Nordisk still looks cheap to me. Lower P/E than Eli Lilly while still being one of the biggest players in GLP-1s. Feels like the selloff got overdone. (Roman, why is there no NVO Ticker?)
Mr. Fool
@mrfool
I trade against the narrative :)
TLT looks good here #whenriskassetsandthedollarlookbadthenlongtermdebtlooksgood #whatdoiknowthough #someonegiveme30shecklesiwannastartaguild
